Chiesi Farmaceutici and NiKem
Research have announced details of their extended research collaboration within
the respiratory therapeutic area. Since 2001 Chiesi and NiKem have collaborated
on several pre-clinical research projects where NiKem provides design,
synthesis, hit validation, lead optimization, biochemical pharmacology, and
ADMET & PK profiling within different therapeutic areas on a
fee-for-service basis.
The current extension
involves the period 2011 to 2014 through a multimillion multi-FTE-based service
agreement on pre-clinical projects of interest for Chiesi in the respiratory
therapeutic area and, in particular, focused on pathologies such as asthma and
COPD.
“The scientific and
business relationship with Chiesi is rock solid and the current extension
follows 10 years of continuous success for both parties in collaborating to
identify novel compounds eligible to candidate status for clinical development,”
says Giuseppe Giardina, CEO of NiKem.
Paolo Chiesi, R&D Director and Vice-President of Chiesi says: “The
collaboration with NiKem was productive and well run by both parties. The
partnership with a single provider for multiple integrated medicinal chemistry
projects is one of the reasons of this successful partnership. It allows use at
best the resources in biochemical pharmacology and ADMET/PK that should support
medicinal chemistry optimization cycles in a flexible format. NiKem has
demonstrated to rapidly adapt to Chiesi needs from time to time, with the
ultimate goal to deliver successful compounds to the clinic.”
NiKem Research, www.nikemresearch.com
Filed Under: Drug Discovery
